Founded in 1998, Gan & Lee Pharmaceuticals is a leading biopharmaceutical company in China specializing in the development, production, and commercialization of insulin analogs and supporting medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters and nearly 3000 employees. With state-of-the-art buildings and GMP facilities, Gan & Lee has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment.
1998 - Developed China’s first recombinant human insulin
2001 - Developed China's first fast-acting insulin analog (lispro)
2002 - Developed China’s first long-acting insulin analog (glargine) and first premixed insulin analog (lispro 25)
2009 - Developed China’s first insulin pen
2013 - Developed second generation insulin pen
2014 - Founded US subsidiary - Gan & Lee Pharmaceuticals USA
2015 - Initiated phase I clinical trial on insulin glargine in Germany
2017 - Initiated phase III clinical trials on insulin glargine in the USA and EU
2019 - Initiated phase I clinical trials on insulin lispro and aspart in the USA and EU
2020 - Initially listed on the A-share index on the Shanghai Stock Exchange
2021 - Completed phase I clinical trials on insulin glargine in Germany
